EUVIMEDEUVIMED entdecken
Crossref

Antiphosphatidylserine/prothrombin antibodies (aPS/PT) and risk of obstetric anti‐phospholipid syndrome

Xiaoxin Zhang, Zhilan Liu, Feng Guo, Qiaohong Wang, Wenxin Bai, Aimin Zhao iD

American Journal of Reproductive Immunology · 2023-06 · 89 (6)

DOI: 10.1111/aji.13621 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Reproductive Immunology, online erschienen am 26.10.2022. Verfasst von Xiaoxin Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, School of Medicine, Renji Hospital, Shanghai Jiaotong University, Shanghai, China. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Assessment of the prevalence of anti‐phosphatidylserine‐prothrombin antibodies (aPS/PT) with OAPS and SN‐OAPS in Chinese patients.

Methods

This retrospective study proceeded at Ren Ji Hospital, Shanghai, China, from January 2019 to January 2020. Two hundred eleven OAPS, 68 SN‐OAPS, 81 disease controls, and 30 healthy donors were enrolled. IgM and IgG aPS/PT, IgM/IgG ‐ aCL, and IgM/ IgG/ anti‐β2GPI antibodies were tested by ELISA while LAC was tested by clotting assays. All the patients were followed up and tested at least twice over 12 weeks apart.

Results

Thirty‐three OAPS (15.64%) and 31 SN‐OAPS (45.59%) were positive for aPS/PT. aPS/PT IgM showed a high Youden index (.813), which classified OAPS and SN‐OAPS patients from healthy controls and other autoimmune diseases. aPS/PT showed a stronger relationship with LAC. Of the 25 OAPS women positive for IgM aPS/PT, 19 (79%) LAC were positive, while of the eight women positive for IgG aPS/PT, 100% were found LAC positive. Conclusion aPS/PT antibody showed an efficient diagnostic value for Chinese patients with OAPS and SN‐OAPS, which could be a potential risk predictor for obstetric complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiphospholipid SyndromePregnancyHumansFemaleAntibodies, AntiphospholipidProthrombinRetrospective StudiesChinaImmunoglobulin GPhosphatidylserinesImmunoglobulin M

Stichwörter der Autor:innen

antiphosphatidylserine/prothrombinobstetric anti-phospholipid syndromepregnancy morbiditiesseronegative antiphospholipid syndromethrombosis

Substanzen

Antibodies, AntiphospholipidProthrombinImmunoglobulin GPhosphatidylserinesImmunoglobulin M

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, School of Medicine, Renji Hospital, Shanghai Jiaotong University, Shanghai, China.
  • Shanghai Key Laboratory of Gynecologic Oncology, Shanghai, China.

ORCID-Profile: Aimin Zhao

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, X., Liu, Z., Guo, F., Wang, Q., Bai, W., & Zhao, A. (2023). Antiphosphatidylserine/prothrombin antibodies (aPS/PT) and risk of obstetric anti‐phospholipid syndrome. American Journal of Reproductive Immunology, 89(6). https://doi.org/10.1111/aji.13621

Vancouver

Zhang X, Liu Z, Guo F, Wang Q, Bai W, Zhao A. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) and risk of obstetric anti‐phospholipid syndrome. American Journal of Reproductive Immunology. 2023;89(6). doi:10.1111/aji.13621

BibTeX
@article{Zhang2023,
  author = {Zhang, Xiaoxin and Liu, Zhilan and Guo, Feng and Wang, Qiaohong and Bai, Wenxin and Zhao, Aimin},
  title = {Antiphosphatidylserine/prothrombin antibodies (aPS/PT) and risk of obstetric anti‐phospholipid syndrome},
  journal = {American Journal of Reproductive Immunology},
  year = {2023},
  volume = {89},
  number = {6},
  doi = {10.1111/aji.13621}
}
Kostenlos starten →